Key result
Lower vitamin D levels were associated with increased high-residual platelet reactivity with ADP-antagonists.
Why the study?
Do lower vitamin D levels predict high-residual platelet reactivity in patients receiving dual antiplatelet therapy after ACS or PCI?
Observational (n=503)
Do lower vitamin D levels predict high-residual platelet reactivity in patients receiving dual antiplatelet therapy after ACS or PCI?
Lower vitamin D levels are associated with higher residual platelet reactivity to ADP-antagonists in patients receiving DAPT after ACS or PCI, suggesting a potential role for vitamin D in antiplatelet resistance.
Answers are grounded in this paper and cite their sources.
Does not support vitamin D testing or supplementation to guide DAPT; leaves open whether levels influence residual platelet reactivity.
BACKGROUND: Suboptimal platelet inhibition still represents an important challenge, especially for patients undergoing percutaneous coronary interventions (PCIs). However, very few are known so far on the predictors of high-residual platelet reactivity (HRPR) despite antiplatelet strategies. Increasing attention has been paid in the last years to the role of vitamin D in atherothrombosis. Therefore, the aim of our study was to evaluate the impact of vitamin D levels on platelet function in patients treated with dual antiplatelet therapy (DAPT). Patients treated with DAPT (ASA and clopidogrel or ticagrelor) after a recent acute coronary syndrome (ACS) or elective PCI were scheduled for platelet function assessment at 30-90 days post-discharge. Platelet function was assessed by whole blood impedance aggregometry (Multiplate®-Roche Diagnostics AG), HRPR was considered for ASPI test values > 862 AU*min (for ASA) and adenosine diphosphate (ADP) test values ≥417 AU*min (for ADP-antagonists). Fasting samples were obtained for main chemistry parameters and vitamin D level assessment. Our population is represented by 503 patients, who were divided according to vitamin D quartiles (≤9.1; 9.2-14.4; 14.5-21.7; >21.7 ng/ml). Lower vitamin D levels related with age (p = 0.04), diabetic status (p = 0.05), and previous coronary surgery (p = 0.007), therapy with beta-blockers and statins (p = 0.01 and p = 0.02). Vitamin D inversely related to the levels of total cholesterol (p = 0.01), triglycerides (p < 0.001), hemoglobin (p = 0.05), and HbA1c (p < 0.001). Significantly higher platelet reactivity was observed after platelet stimulation with ADP (p = 0.01), but not with other platelet activators. The prevalence of HRPR for ASA was low (1.2%) and not conditioned by Vitamin D levels (adjusted OR[95%CI] = 1.56[0.71-3.5], p = 0.27). HRPR with ADP-antagonists was observed in 26% of patients, and the rate increased with lower vitamin D quartiles (37.3% vs 22.2% vs 24.4% vs 20.2%, p = 0.005, adjusted OR[95%CI] = 1.23[1.02-1.49], p = 0.04). An absolute increase in HRPR with lower vitamin D levels was similarly observed among patients receiving ticagrelor (adjusted OR[95% CI] = 1.40[0.95-2.06], p = 0.08), and those on clopidogrel (adjusted OR[95%CI] = 1.31[0.99-1.75], p = 0.06). Thus, lower vitamin D levels are associated with higher platelet reactivity and impaired effectiveness of ADP-antagonists, while not influencing the effectiveness of ASA. Future studies will tell whether vitamin D supplementation can reduce platelet reactivity, overcoming the phenomenon of resistance to antiplatelet agents.
No takes yet. Share an insight, caveat, or question.
Verdoia et al. (2016) conducted an observational in Acute coronary syndrome or elective PCI on DAPT (n=503). Lower vitamin D levels vs. Higher vitamin D levels was evaluated on High-residual platelet reactivity (HRPR) with ADP-antagonists (OR 1.23, 95% CI 1.02-1.49, p=0.04). Lower vitamin D levels were associated with increased high-residual platelet reactivity with ADP-antagonists.
Synapse has enriched 10 related papers. Consider them for comparative context: